Jack the Sparow / Shutterstock.com

5 November 2024NewsAmericasMarisa Woutersen

Sanofi subsidiary fends off $450m trade secrets case

A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Sanofi signs global rights deal to develop rare cancer therapy

13 September 2024 Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.

LSPN Fall: Why Big Pharma is facing 'a balancing act'

17 October 2024 As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.

More on this story

Biotechnology

Sanofi signs global rights deal to develop rare cancer therapy

13 September 2024 Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.

LSPN Fall: Why Big Pharma is facing 'a balancing act'

17 October 2024 As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.

More on this story

Biotechnology

Sanofi signs global rights deal to develop rare cancer therapy

13 September 2024 Sanofi will be responsible for global commercialisation of the medicine, used to treat neuroendocrine tumours | Pharma giant will pay up to $320m plus royalties to two biotech companies.

LSPN Fall: Why Big Pharma is facing 'a balancing act'

17 October 2024 As the pharma sector grapples with legal and regulatory upheaval, LSPN Fall North America explored the need for companies to reassess their patent strategies. Marisa Woutersen reports.

More features

LSPN Europe: Navigating the EPO and lessons from the UPC’s frontline

Paul Hastings reinforces London office with high-tech patent litigator

Gene tech firm fends off injunction in test kit dispute

Comparing life sciences IP in Brazil and the US

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings